Latest! China RA treatment or will enter the era of precision.

It is a way to pay attention to and explore the treatment plan for patients through antibody status, and the accumulation of relevant research results also provides valuable evidence-based medical evidence for targeted drug selection.
rheumatoid arthritis (RA) is a common chronic, highly disabling autoimmune disease that has long been considered an "undead cancer".
more and more clinical studies have found that autoantibodies and RA incidence, disease and efficacy prediction have a certain relationship, especially the relationship between anticycline peptide antibodies (ACPA) and RA efficacy has become a hot research topic in recent years.
ACPA is present in 70% of RA patients and is observed to have been produced in the body in the first few years or even more than a decade.
ACPA (plus) people are not only more likely to develop to RA, but also play an important role in the progression of the disease.
Sweden's Professor Daha's 2011 article in Nature Reviews Rheumatology suggests that ACPA (plus) and ACPA (-) RA may not be a disease, depending on the ACPA status.
but since there are differences in morbidity and complications, why is ACPA not included in the new diagnosis RA as the basis for treatment options? The reason may be that serological states may have no effect on the efficacy of MTX first-line therapy, and ACPA as one of the factors of adverse development is the choice of the second stage treatment regimen.
the following is an inventory of the relevant research results for 2020: ACPA may be an independent factor predicting the effectiveness of certain bDMARD treatments, the 2014 AMPLE study showed that abassand and Adamu monotomojaefficey were comparable in RA patients who had used biologics and methotrexate (MTX) in efficacy, and subgroup analysis showed that patients with the highest baseline ACPA had a better clinical response than patients with lower levels of abisnaps.
's AMPLE study, published in EULAR this year, compared the efficacy of abassapu and Adamu monotoma in patients with aCPA plus.
the trial lasted 48 weeks and involved 80 patients: 40 in the Abasspu group and 40 in the Adamu monoantigen group, with two sets of baseline features balanced and multiple exploration endpoints (changes in autoantibody levels, changes in cytokines, changes in the percentage of immune cells subgroup, and changes in the activation status of immune cell subgroups). After 48 weeks of
treatment, the abrasive rate of ACR20/50/70 or DAS28 was better than that of the Adamu monotodrine group, and the efficacy index of patients who started with Adamu monotomatoris was converted to Abassuptreatment.
the researchers also carried out subgroup analysis based on the patient's HLA-DRB1 gene SE status (-, no SE allele genes; s1SE allele genes).
in SE patients, Abassup's efficacy is similar to that of the previous.
, a higher rate and persistence of ACR20/50/70 response to aBRAina after 48 weeks of treatment in patients with ACPA plus, early RA, especially in the SE-subgroup, and patients who started with ADA treatment had significantly improved outcomes after conversion to ABA therapy.
THE EARLY AMPLE STUDY NOT ONLY SUPPORTS ABASSAPU AS A FIRST-LINE TREATMENT FOR PATIENTS WITH MODERATE AND SEVERE RA, BUT ALSO FURTHER CLARIFIES THE BENEFICIARIES OF ABASSUP'S TREATMENT.
, the study also promotes an understanding of the pathogenesis of moderate to severe RA and demonstrates the value of the suitability of precision drugs for patients with highly active and progressive rheumatoid arthritis. are real-world data
consistent with THE AMPLE study? This year, a U.S. study comparing the clinical benefits of Abaabe in the Real World (RW) Environment and Experimental Environment (AMPLE) came out.
the retrospective study obtained clinical data from 291 RA patients treated with Abassup, and compared with previous AMPLE data, it was found that the improvement rate of both the number of tenderal joints (TJC), the number of swollen joints (SJC), and the ACR20/50 ratio were similar to those of THE AMPLE study.
show that Abassup's efficacy in treating RA patients in the real world is similar to that in clinical studies.
Asian patients have results similar to those in the AMPLE study? A real-world study from Japan analyzed data on 553 patients treated with Abassi for more than 52 weeks from the BiologicS Therapeutics Multicenter Registration System.
compare the status of disease activity (SDAI) and imaging (mTSS) in ACPA plus (446 cases) and ACPA-patients (107 cases). The SDAI of the
positive results group improved more significantly from baseline to 52 weeks than the negative group, and the proportion of patients who reached low mobility (LDA) significantly higher.
in single-variable and multivariate logistics regression, ACPA plus is the independent predictor of reaching LDA in the 52st week.
concludes that RA is a slow progress, heterogeneous disease, patient's individual treatment has been a hot topic of clinical experts and the direction of efforts.
about 80% of RA patients abroad have been widely used for biological therapy, domestic RA patients more than 5 million and increasing year by year, but the proportion is even less than 5%. Behind
strong contrasts are huge and unmet clinical needs.
combined with the basic and clinical research results of the relationship between this type of antibody and ABA treatment, we can clearly see that the choice of more suitable treatment plan for patients through antibody status is a way to be concerned and explored, and the continuous accumulation of relevant research results also provides valuable evidence-based medical evidence for targeted drug selection.
the lack of a ptae of aCPA in the past clinically is due to the lack of effective drugs for ACPA, Abasspu injection is approved for sale in China's first and only CTLA4-Fc fusion protein, is the world's first and only selective T-cell co-stimulation regulator in the field of autoimmune therapy, his presence will effectively fill this gap, thus further leading THE RA treatment into the era of precision treatment.
References: Siolove J, Schiff M, Fleischmann R, et al. Impact of the baseline anti-cyclic citrullinated peptide-2 antibody-hub on-the-effic-outcome-ac treatment with subcutanabateth ordali Annals of the Rheumatic Diseases, 2016, 75 (4): 709-714. S. Schiff M, Weinblatt ME, Valente R, et al. Head-to-head comparison of subcutane abatacept versus adalimumab for rheumat arthritis: two-year-years-effic and eafod. Annals of the rheumatic diseases, 2014, 73 (1): 86-94, Rigby W, Buckner J, Bridges, Jr. SL, et alTHU0160 THE EFFECT OF HLA-DRB1 RISK ALLELES ON THE THA CLINICAL ETHEPT IN SEROESANDY OF ABATACEPT IN SEROES, THONIC-NA-NAVES PATIENTES WITH AMPLE' TRIALANNALs of the Rheumatic Diseases 2020; 79:295. Klink A, Han X, Lobo F, et alFRI0096 CLINICAL BENEFITS IN AMPLE IN OBSERVED IN A REAL-WORLD (RW) COHORT OF US RHEUMAT ARTHRITIS (RA) PATIENTSAnnALs of Theeumatic Diseases 2020; 79:626-627. Takahashi N, Kojima T, Asai S on Bebehalf of TBCR Study Group, et alFRI0107 EFFECTIVENESS OF ABATACEPT ON CLINICAL DISEASE ACTIVITY AND RADIOGRAPHIC PROGRESSION IN RHYSATATOIDS PATIENTS IN DAY CLINICAL IN TING SEIN TATS: